Quanterix Corporation (NASDAQ:QTRX) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Masoud Toloue - President, CEO Mike Doyle - CFO Conference Call Participants Puneet Souda - SVB Leerink Max Masucci - Cowen Matt Sykes - Goldman Sachs Operator Hello, thank you for standing by. And Welcome to the Quanterix Corporation Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20-8957988 (Stat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20-8957988 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) 20-8957988 (I.R.S. Employer Ide ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20-8957988 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20-8957988 (Stat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20-8957988 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20-8957988 ...

Financial Data and Key Metrics Changes - Revenue in Q2 2020 was $13.1 million, a decrease of 3% compared to the previous year, primarily impacted by the COVID-19 pandemic [64] - Year-to-date total revenues reached $28.9 million, reflecting a 12% increase [65] - Non-GAAP gross margin for Q2 was 44.1%, down from 51.2% in the prior year, influenced by the HD-1 trade-in program and lower cost absorption due to reduced consumables revenue [66][67] Business Line Data and Key Metrics Changes - Instrument revenue was $2.8 million, consistent with the prior year despite access challenges [64] - Consumables revenue finished at $4 million, a decline of 34% compared to the previous year [65] - Services revenue increased by 33% to $6.3 million, driven by expanded Accelerator services capacity [65] Market Data and Key Metrics Changes - North America saw a growth of 27%, while Europe and Asia experienced faster growth [53] - The academic sector has been slower to recover compared to pharma, with a strong focus on COVID-related research [99] Company Strategy and Development Direction - The company aims to leverage its Simoa technology for earlier and less invasive disease detection, particularly in neurology and infectious diseases [12][19] - There is a focus on expanding into the diagnostics market, with aspirations to partner with IVD companies [24][48] - The company anticipates a long-term revenue growth target of 30% to 40%, primarily driven by research, with potential for diagnostics to enhance this growth [78][81] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about recovering to a strong growth trajectory in the second half of the year despite ongoing challenges from the pandemic [69] - The company is seeing positive momentum in its Accelerator services and anticipates further growth in consumables as pharma trials ramp up [94] Other Important Information - The company has secured significant contracts, including a $1 million contract with a large payer group and a feasibility study with the NIH [75][80] - The number of third-party peer-reviewed publications has approached 900, with a significant focus on neurology [49] Q&A Session Summary Question: What is the source of incremental demand for the Accelerator? - Management noted that demand is coming from both new customers and existing customers utilizing newer technologies for immune system studies and COVID-related research [72][74] Question: How does the recent progress impact long-term revenue growth targets? - The growth target remains strong, with advancements in diagnostics expected to enhance the research business, although significant revenue from diagnostics may take a year or two to materialize [77][81] Question: What is the expected recovery trajectory for the services business? - The services business is expected to continue growing, supported by large population studies and the ability to conduct testing with small sample sizes [92][93] Question: How is the academic sector expected to recover? - The academic sector is beginning to reopen, with interest in COVID-related research, and the company anticipates good instrument and consumable pull-through as labs return to normal operations [98][99]